PharmAust has given US-based manufacturer Catalent the green light to start producing more Good Manufacturing Practice-grade Monepantel tablets for its upcoming Phase 2 anti-cancer clinical trials in dogs. The company plans to start recruiting dogs with B cell lymphoma in August or September this year for the Phase 2 trials, which will initially follow a 28-day treatment regimen.
04/06/2019 - 10:54
PharmAust starts tablet production for Phase 2 cancer trials
By Matt Birney
04/06/2019 - 10:54
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 137th Adisyn $2.9m 138th rent.com.au $2.8m 141st Douugh $2.5m 142nd Hazer Group $2.4m 201 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Related Articles
24 Apr 2024
Board Moves, April 24 2024
23 Apr 2024
PharmAust CEO resigns
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX